SCHEMBL26655

SCHEMBL26655

COC(OC(OC)c1ccccc1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
EPHX1 P07099 1/20 0.39
THRB P10828 1/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
CA4 P22748 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
DPP4 P27487 2/20 0.38
F2 P00734 1/20 0.38
TSHR P16473 1/20 0.38
MEN1 O00255 3/20 0.37
MAPT P10636 2/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6359298 1.00 KMT2A (0.41) KMT2AEPHX1THRBIDO1TDO2
SCHEMBL26689 0.89 KMT2A (0.44) KMT2AEPHX1THRBIDO1TDO2
SCHEMBL12261012 0.88 THRB (0.40) KMT2AEPHX1THRBIDO1TDO2
Iodide SCHEMBL27504755 0.86 KMT2A (0.43) KMT2AEPHX1THRBIDO1TDO2
Lithium SCHEMBL30301644 0.86 KMT2A (0.43) KMT2AEPHX1THRBIDO1TDO2
SCHEMBL28261380 0.84 KMT2A (0.39) KMT2AEPHX1THRBTSHRMEN1
SCHEMBL10607695 0.84 KMT2A (0.41) KMT2AEPHX1THRBIDO1TDO2
SCHEMBL18688775 0.81 TRPA1 (0.40) KMT2ATSHRMEN1ATML3MBTL1
SCHEMBL14660344 0.80 KMT2A (0.43) KMT2AEPHX1THRBIDO1TDO2
SCHEMBL18940434 0.80 KMT2A (0.39) KMT2AEPHX1THRBIDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 649 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240141362-A1 MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY UNIV MASSACHUSETTS (US) 2024-05-02 US claimed
US-11820985-B2 Modified oligonucleotides with increased stability UNIVERSITY OF MASSACHUSETTS (US) 2023-11-21 US claimed
EP-4203940-A1 METHODS TO PRODUCE VERY LONG CHAIN FATTY ACIDS (VLCFA) The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2023-07-05 EP claimed
EP-3946369-A2 MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY University Of Massachusetts (US) 2022-02-09 EP claimed
CN-112175265-A Modified color master batch and preparation method thereof 方少山 2021-01-05 CN claimed
US-20200385740-A1 MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY UNIVERSITY OF MASSACHUSETTS 2020-12-10 US claimed
EP-3746509-A1 BUGPHOBIC AND ICEPHOBIC COMPOSITIONS WITH FLUID ADDITIVES HRL Laboratories, LLC (US) 2020-12-09 EP claimed
WO-2020198509-A2 MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY UNIVERSITY OF MASSACHUSETTS (US) 2020-10-01 WO claimed
CN-106573904-B Method for generating beraprost and its derivative 朗格生物技术公共公益股份有限公司 2019-11-08 CN claimed
CN-106458923-B Heterocyclic compound 株式会社大熊制药 2019-09-10 CN claimed
CN-100355772-C Steroid compound with 5-alpha reductase active and preparation process thereof UNIV TIANJIN (CN) 2007-12-19 CN claimed
WO-2007088186-A1 NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2007-08-09 WO claimed
WO-2006127893-A2 PROCESSES FOR PRODUCTION OF 4-(BIPHENYLYL)AZETIDIN-2-ONE PHOSPHONIC ACIDS MICROBIA, INC. (US) 2006-11-30 WO claimed
WO-2006122020-A2 PROCESS FOR PRODUCTION OF 4-BIPHENYLYAZETIDIN-2-ONES MICROBIA, INC. (US) 2006-11-16 WO claimed
WO-2006122216-A2 PROCESSES FOR PRODUCTION OF PHENOLIC 4-BIPHENYLYLAZETIDIN-2-ONES MICROBIA, INC. (US) 2006-11-16 WO claimed
EP-1363640-A4 NUCLEIC ACID DERIVATIVES BIO RAD LABORATORIES (US) 2006-10-25 EP claimed
CN-1793164-A Steroid compound with 5-alpha reductase active and preparation process thereof UNIV TIANJIN (CN) 2006-06-28 CN claimed
EP-1363640-A2 NUCLEIC ACID DERIVATIVES BIO-RAD LABORATORIES, INC. (US) 2003-11-26 EP claimed
US-20030191074-A1 Nucleic acid derivatives BIO-RAD LABORATORIES INC. 2003-10-09 US claimed
WO-2002061110-A2 NUCLEIC ACID DERIVATIVES BIO-RAD LABORATORIES, INC. (US) 2002-08-08 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191074-A1 Nucleic acid derivatives NSUN2, POLRMT, ADAR KMT2A 1273/4885EPHX1 4817/4885THRB 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.